License agreement for development and sales of new anti-ulcerant

Published: 2010-04-28 06:59:00

Updated: 2010-04-28 06:59:00

Choong-wae Pharm concluded a license agreement with Mitsubishi Tanabe Pharma on April 26, granting Choong-wae exclusive rights in Korea for the development and sale of S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls).

Choong-wae will now advance clinical development in preparation for a new drug ap...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.